A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis
Crossref DOI link: https://doi.org/10.1177/1756283X17705329
Published Online: 2017-04-25
Published Print: 2017-06
Update policy: https://doi.org/10.1177/sage-journals-update-policy
Iwakiri, Katsuhiko
Sakurai, Yuuichi
Shiino, Madoka
Okamoto, Hiroyuki
Kudou, Kentaro
Nishimura, Akira
Hiramatsu, Naoki
Umegaki, Eiji
Ashida, Kiyoshi
Funding for this research was provided by:
Takeda Pharmaceutical Company Limited
Text and Data Mining valid from 2017-04-25
